{
    "id": "dbpedia_8094_2",
    "rank": 96,
    "data": {
        "url": "https://slideplayer.com/slide/4650138/",
        "read_more_link": "",
        "language": "en",
        "title": "Investors’ Day at Olainfarm September 14, 2007 Company Presentation.",
        "top_image": "",
        "meta_img": "",
        "images": [
            "https://slideplayer.com/static/blue_design/img/logo_slideplayer.png",
            "https://slideplayer.com/static/blue_design/img/slide-loader4.gif",
            "https://images.slideplayer.com/15/4650138/slides/slide_1.jpg",
            "https://images.slideplayer.com/15/4650138/slides/slide_2.jpg",
            "https://images.slideplayer.com/15/4650138/slides/slide_3.jpg",
            "https://images.slideplayer.com/15/4650138/slides/slide_4.jpg",
            "https://images.slideplayer.com/15/4650138/slides/slide_5.jpg",
            "https://images.slideplayer.com/15/4650138/slides/slide_6.jpg",
            "https://images.slideplayer.com/15/4650138/slides/slide_7.jpg",
            "https://images.slideplayer.com/15/4650138/slides/slide_8.jpg",
            "https://images.slideplayer.com/15/4650138/slides/slide_9.jpg",
            "https://images.slideplayer.com/15/4650138/slides/slide_10.jpg",
            "https://images.slideplayer.com/15/4650138/slides/slide_11.jpg",
            "https://images.slideplayer.com/15/4650138/slides/slide_12.jpg",
            "https://images.slideplayer.com/15/4650138/slides/slide_13.jpg",
            "https://images.slideplayer.com/15/4650138/slides/slide_14.jpg",
            "https://images.slideplayer.com/15/4650138/slides/slide_15.jpg",
            "https://images.slideplayer.com/15/4650138/slides/slide_16.jpg",
            "https://images.slideplayer.com/15/4650138/slides/slide_17.jpg",
            "https://images.slideplayer.com/15/4650138/slides/slide_18.jpg",
            "https://images.slideplayer.com/15/4650138/slides/slide_19.jpg",
            "https://images.slideplayer.com/15/4650138/slides/slide_20.jpg",
            "https://images.slideplayer.com/15/4650138/slides/slide_21.jpg",
            "https://images.slideplayer.com/15/4650138/slides/slide_22.jpg",
            "https://images.slideplayer.com/15/4650138/slides/slide_23.jpg",
            "https://images.slideplayer.com/15/4650138/slides/slide_24.jpg",
            "https://images.slideplayer.com/15/4650138/slides/slide_25.jpg",
            "https://images.slideplayer.com/15/4650138/slides/slide_26.jpg",
            "https://images.slideplayer.com/15/4650138/slides/slide_27.jpg",
            "https://images.slideplayer.com/15/4650138/slides/slide_28.jpg",
            "https://images.slideplayer.com/15/4650138/slides/slide_29.jpg",
            "https://images.slideplayer.com/15/4650138/slides/slide_30.jpg",
            "https://slideplayer.com/2/730883/big_thumb.jpg",
            "https://slideplayer.com/4/1445755/big_thumb.jpg",
            "https://slideplayer.com/5/1495734/big_thumb.jpg",
            "https://slideplayer.com/11/3259354/big_thumb.jpg",
            "https://slideplayer.com/12/3385458/big_thumb.jpg",
            "https://slideplayer.com/13/3842678/big_thumb.jpg",
            "https://slideplayer.com/13/3925217/big_thumb.jpg",
            "https://slideplayer.com/13/4063306/big_thumb.jpg",
            "https://slideplayer.com/14/4260383/big_thumb.jpg",
            "https://slideplayer.com/14/4272654/big_thumb.jpg",
            "https://slideplayer.com/15/4578196/big_thumb.jpg",
            "https://slideplayer.com/15/4787622/big_thumb.jpg",
            "https://slideplayer.com/16/4909437/big_thumb.jpg",
            "https://slideplayer.com/17/5345511/big_thumb.jpg",
            "https://slideplayer.com/19/5729197/big_thumb.jpg",
            "https://slideplayer.com/19/5773487/big_thumb.jpg",
            "https://slideplayer.com/19/5903053/big_thumb.jpg",
            "https://slideplayer.com/20/5937966/big_thumb.jpg",
            "https://slideplayer.com/20/6009288/big_thumb.jpg",
            "https://slideplayer.com/20/6017068/big_thumb.jpg"
        ],
        "movies": [],
        "keywords": [],
        "meta_keywords": [
            "Investors’ Day at Olainfarm September 14",
            "2007 Company Presentation."
        ],
        "tags": null,
        "authors": [],
        "publish_date": null,
        "summary": "",
        "meta_description": "Governing Structure Shareholders meeting Council - Supervisory body, which represents the shareholders' interests between the Shareholders’ meetings - Consists of 5 members, elected by shareholders for 3 years - Elects and dismisses members of the Board Board - Executive body, which manages and represents the company - Responsible for commercial activities of the company - Composed of 5 members (recently reduced down from 7), elected for 3 years",
        "meta_lang": "",
        "meta_favicon": "",
        "meta_site_name": "",
        "canonical_link": "https://slideplayer.com/slide/4650138/",
        "text": "Presentation on theme: \"Investors’ Day at Olainfarm September 14, 2007 Company Presentation.\"— Presentation transcript:\n\n1 Investors’ Day at Olainfarm September 14, 2007 Company Presentation\n\n2 OlainFarm: at a glance - 35 years since established, 10 years since privatized - Produces both FDFs and full cycle APIs - Annual sales have more than doubled over the past 3 years - Strong and seasoned management team - ISO 14001 (2001:2007), FDA (USA - APIs only, 2002) and GMP (EU 2004:2007)‏ Major shareholders: - Olmafarm (sole shareholder is OlainFarm’s Chairman of the Board Valerijs Maligins) - Juris Savickis\n\n3 Governing Structure Shareholders meeting Council - Supervisory body, which represents the shareholders' interests between the Shareholders’ meetings - Consists of 5 members, elected by shareholders for 3 years - Elects and dismisses members of the Board Board - Executive body, which manages and represents the company - Responsible for commercial activities of the company - Composed of 5 members (recently reduced down from 7), elected for 3 years\n\n4 Main Markets - Main focus on home market and the CIS - Central and Western Europe growing mainly through APIs and intermediates - Diversification of markets - Over 200 medical representatives in key markets - Sales to 25 countries, subsidiary in Russia\n\n5 Main Markets (continued) - On average the sales grow faster than markets (about 15%)‏ - Branding has slowed growth in Russia in terms of sales, not profit - Specific products influenced significant growth in the UK and Kazakhstan - Very limited exposure to Russian DLO Program (about 200 000 LVL)‏\n\n6 Key Products\n\n7 - Antihistamine - Sold as Bikarfen or Gistafen in selected markets - Limited clinical tests conducted to strengthen sales - Sales of antihistamines in our markets: approx 105 M LVL - Maximum sales: 4.2 M LVL p.a. Key Products - Fenkarol\n\n8 - Nootropic drug - Sold as Fenibut in Russia and as Noofen elsewhere - Cost efficient synthesis - Participation in Russian DLO. Program discontinued in 2007, which caused slight drop in sales - Total sales of this product group in our markets: 140 M LVL - Maximum sales: 4.5 M LVL p.a. Key Products - Fenibut\n\n9 - Cholinesterase inhibitor - Cost efficient chemical synthesis - Total sales of this product group in our markets: approx 300 M LVL as this is a multi- purpose drug for CNS related indications - Maximum sales: 7 M LVL p.a. Key Products - Neiromidin\n\n10 Key Products - Furagin - Nitrofurantoine derivative, anti- infective drug - In process of replacement of Furagin with Furamag - In sachets sold as Furasol - Olainfarm is the only stable API producer in traditional markets -Total sales of this product group in our markets: 70 M LVL - Maximum sales: 4.5 M LVL p.a.\n\n11 Key Products – PASA Sodium Salt - Anti tuberculosis drug, helps to treat resistant forms of tuberculosis - So far sold solely to governmental programs, thus sales are difficult to forecast - World market approx. 300 M EUR - Maximum sales: 5 M LVL p.a., limited by current production capacities - Files are being prepared for WHO registration, allowing for worldwide sales\n\n12 New Products – Current Status Meldonium -Generic drug for treatment of cardio vascular diseases, original among TOP 15 best selling drugs in Russia and TOP 3 best seller in Ukraine - Current status: Registration files are being finished, bioequivalence tests started in Ukraine - Expected launch: 2008 Expected sales in 2012 - LVL 4.5 mln\n\n13 stat New Products – Current Status Olvazol ® - Patent protected next generation of Meldonium - Fast acting drug for prophylaxis and treatment of ischemic heart and brain injury and infarction - Current status: undergoing stability tests, clinical pilot trials to be started by the end of 2007. - Expected launch: 2009 Expected sales in 2012 - LVL 4.5 mln\n\n14 New Products – Current Status R-Fenibut -Pure enantiomeric form of known drug, at least 2x more effective than a parent drug, thus requires ½ of dosage or less -Fewer side effects -Current status: scale-up and fine-tuning of technology under way, clinical pre-trials to be started before the end of 2007 -Expected launch: 2009 Expected sales in 2012 - LVL 3.2 mln\n\n15 New Products – Current Status R-Fenotropil -New patented molecule, at least 2x more effective as parent drug, thus requires ½ of dosage or less and has fewer side effects -Current status: scale-up and fine-tuning of technology under way, pre- clinical trials to be started before the end of 2007 -Expected launch: 2009 Expected sales in 2012 - LVL 4.0 mln\n\n16 New Products – Current Status Memantine - Widely used for treatment of Alzheimer’s disease, running out of patent protection - Olainfarm developed technology for worldwide sales - Exclusive co-operation with a multinational company, Olainfarm will sell Memantine in CEE, CIS and Middle East - Current status: registration by partner started in Germany, Canada; Olainfarm is finishing file to be submitted for registration early 2008 - Expected launch: 2009 (limited markets)‏ Expected sales in 2012: LVL 7.5 mln (subject to patent protection)‏\n\n17 New Products – Current Status New Generics Program for Baltics -First stage includes five new first generics for the Baltic states, two for treatment of fungus, two for CNS diseases and one cardiovascular medicine -Three of the five will be registered through Baltic MRP procedure -Currens status: registration under way -Expected launch: 2008 Expected sales in 2012 - LVL 2.1 mln\n\n18\n\n19 - Existing FDF products: - more marketing effort, branding, additional comparative tests; - strengthened network of medical representatives; - new forms and dosages of products; - new markets within FSU countries; - natural market growth; - price increases. - New FDF products: - higher added value; - patent protected. - APIs and intermediates - improved recognition of Olainfarm in the global market; - UK already among top markets. Where will the growth come from?\n\n20 Historic performance\n\n21 Seasonality\n\n22 Historic performance - Margins\n\n23 Historic Performance - Assets\n\n24 Historic Performance - Equity and Liabilities\n\n25 Share performance in 2007 -- Olainfarm -- OMX Riga\n\n26 Share performance in 2007 -- Olainfarm -- OMX Nordic EUR GI\n\n27 Investment Alternatives in 2007 Since January 1, 2007: - DAX +12.55% - Nikkei 225 -7.83% - S&P 500 +2.36% - CAC40 -2.11% - FTSE 100 -0.54% - SSMI -1.4%\n\n28 IPO of June 2007 - 876 023 shares subscribed; 2 584 267.85 LVL raised - Post issue number of shares: 14 085 078 - Raised amounts allowed to proceed with smaller items of CAPEX program, including warehousing and some production units - Ampouling facility project postponed, not abandoned\n\n29 Considerations for Further Activities - Partial issue allowed to attract some leverage; - Considerable CAPEX needs remain for 2008 and further years, especially as new products get launched into market; - Limited possibilities for further significant leverage; - Board and the Council to elaborate proposals by the end of this year."
    }
}